LET for Fibromyalgia

The study is a double blinded, randomized, sham-controlled, parallel group trial conducted at UT Southwestern (UTSW) Medical Center. The purpose of this research study is to determine the effectiveness of Lymphatic Enhancement Technology (LET) treatment in patients with fibromyalgia. Participants will complete assessments of heart rate and blood pressure, pain thresholds to mechanical stimuli, and completion of quality-of-life surveys. In addition, participants will receive four treatments, one time per week, with either an active or sham LET device. Each visit will take between 45 minutes to 2 hours. A follow-up phone call or email from the study team will occur at 4 weeks after completion of the LET treatment. Total study duration is two months.

NCT Number	NCT07201818
Lead Sponsor	University of Texas Southwestern Medical Center Collaborators: Arcturus Star Products
Conditions	Fibromyalgia
Enrollment	40 participants
Start Date	2026-06
Primary Completion	2027-10 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-20